Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29459625 | 1.00 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Hydrochloric Acid SCHEMBL8168636 | 0.99 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| SCHEMBL20983505 | 0.90 | MRGPRX2 (0.82) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Methoxymethane SCHEMBL27466715 | 0.89 | MRGPRX2 (0.94) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL29449917 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL154048 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL29583693 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL20522476 | 0.88 | MRGPRX2 (0.78) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Hydrochloric Acid SCHEMBL27754570 | 0.87 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL6157352 | 0.87 | MRGPRX2 (0.77) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628216-B2 | 6-acetylmorphine analogs, and methods for their synthesis and use | ALERE SAN DIEGO, INC. (US) | 2023-04-18 | — | — | US | claimed |
| US-20220080042-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. | 2022-03-17 | — | — | US | claimed |
| EP-3470416-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | Alere San Diego, Inc. (US) | 2019-04-17 | — | — | EP | claimed |
| US-20180353597-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. (US) | 2018-12-13 | — | — | US | claimed |
| US-10052379-B2 | 6-acetylmorphine analogs, and methods for their synthesis and use | ALERE SAN DIEGO, INC. (US) | 2018-08-21 | — | — | US | claimed |
| US-20170296654-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. | 2017-10-19 | — | — | US | claimed |
| US-20170189902-A1 | READY-TO-CONSTITUTE ANALYTICAL PLATFORMS FOR CHEMICAL ANALYSES AND QUANTIFICATION | PINPOINT TESTING, LLC (US) | 2017-07-06 | — | — | US | claimed |
| WO-2016040822-A1 | READY-TO-CONSTITUTE ANALYTICAL PLATFORMS FOR CHEMICAL ANALYSES AND QUANTIFICATION | PINPOINT TESTING, LLC (US) | 2016-03-17 | — | — | WO | claimed |
| US-20160022809-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. | 2016-01-28 | — | — | US | claimed |
| EP-2970319-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | Alere San Diego, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152657-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | DURECT CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-5952495-A | REACTING WITH HYDROGEN PEROXIDE AT A TEMPERATURE FROM 15.DEGREE. C. TO ABOUT 70.DEGREE. C. IN THE PRESENCE OF AN ACID AND AN AQUEOUS SOLVENT; FORMING A KEY INTERMEDIATE FOR IMPORTANT NARCOTIC ANALGESICS AND ANTAGONISTS | PENICK CORPORATION (US) | 1999-09-14 | — | — | US | disclosed |
| US-5948788-A | Normorphine and normorphinone derivatives | PENICK CORPORATION (US) | 1999-09-07 | — | — | US | disclosed |
| US-5922876-A | REACTING MORPHINE WITH ACYL HALIDE OR ANHYDRIDE TO FORM 3-ACYLMORPHINE, OXIDIZING HYDROXY GROUP OF ACYLMORPHINE WITH AN OXIDIZING AGENT, REACTING THE INTERMEDIATE WITH HYDROGEN PEROXIDE AND AN ACID, ACYLATING, HYDROGENATING AND HYDROLYSIS | PENICK CORPORATION (US) | 1999-07-13 | — | — | US | disclosed |
| US-5869669-A | REACTING WITH AN OXIDIZING AGENT IN THE PRESENCE OF A WEAK ACID | PENICK CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1999002529-A1 | PREPARATION OF OXYMORPHONE, OXYCODONE AND DERIVATIVES | PENICK CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | OPRK1, OPRD1, OPRM1 | MRGPRX2 379/4885OPRM1 3/4885OPRK1 1/4885 |
| US-20220080042-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | DNPEP, CRHBP, AANAT | MRGPRX2 347/4885OPRM1 11/4885OPRK1 13/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | MRGPRX2 178/4885OPRM1 6/4885OPRK1 7/4885 |
| US-11628216-B2 | 6-acetylmorphine analogs, and methods for their synthesis and use | DNPEP, CRHBP, AANAT | MRGPRX2 347/4885OPRM1 11/4885OPRK1 13/4885 |
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | SLC10A2, OPRK1, HBB | MRGPRX2 2512/4885OPRM1 5/4885OPRK1 2/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | MRGPRX2 1275/4885OPRM1 4810/4885OPRK1 2862/4885 |
| US-20180353597-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | DNPEP, CRHBP, AANAT | MRGPRX2 347/4885OPRM1 11/4885OPRK1 13/4885 |
| US-20160022809-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | DNPEP, CRHBP, AANAT | MRGPRX2 347/4885OPRM1 11/4885OPRK1 13/4885 |
| US-10052379-B2 | 6-acetylmorphine analogs, and methods for their synthesis and use | DNPEP, CRHBP, AANAT | MRGPRX2 347/4885OPRM1 11/4885OPRK1 13/4885 |
| US-20170296654-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | DNPEP, CRHBP, AANAT | MRGPRX2 347/4885OPRM1 11/4885OPRK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.